Stockreport

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease [Canadian Business Journal (Canada)]

ProMIS Neurosciences Inc. - Common Shares  (PMN) 
PDF Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s DiseaseSix-month Interim Results Expect [Read more]